Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts $119.93 -2.77 (-2.26%) (As of 12/3/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ligand Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ligand Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataLGND Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.LGND Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Weiss RatingsOne coin could soar when Trump’s elected …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. Ligand Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241$0.75$0.75$0.75 Q2 20241$0.67$0.67$0.67 Q3 20241$0.80$0.80$0.80 Q4 20241$0.75$0.75$0.75 FY 20244$2.97$2.97$2.97 Q1 20251$0.98$0.98$0.98 Q2 20251$1.01$1.01$1.01 Q3 20251$1.00$1.00$1.00 20253$2.99$2.99$2.99 Q1 20261$1.19$1.19$1.19 Ligand Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 2/25/2025(Estimated)-------8/6/2024Q2 2024$1.06$1.40+$0.34$4.72$33.04M$41.50M5/7/2024Q1 2024$0.83$3.84+$3.01-$3.15$27.92M$30.90M2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54M$28.10M11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22M$32.87M8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74M$26.37M5/4/2023Q1 2023$0.89$2.28+$1.39$1.59$33.55M$43.98M Get the Latest News and Ratings for LGND and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/22/2023Q4 2022$1.23$1.36+$0.13$0.52$39.63M$50.40M Ligand Pharmaceuticals Earnings - Frequently Asked Questions When is Ligand Pharmaceuticals's earnings date? Ligand Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on LGND's earnings history. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2024 earnings guidance on Thursday, November, 7th. The company provided earnings per share guidance of 5.500-5.700 for the period, compared to the consensus earnings per share estimate of 5.390. The company issued revenue guidance of $160.0 million-$165.0 million, compared to the consensus revenue estimate of $156.4 million. How much revenue does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $131.31 million. How much profit does Ligand Pharmaceuticals generate each year? Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $52.15 million. LGND has generated $2.51 earnings per share over the last four quarters. What is Ligand Pharmaceuticals's price-to-earnings ratio? Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 47.78 and a forward price-to-earnings ratio of 69.32. What is Ligand Pharmaceuticals's EPS forecast for next year? Ligand Pharmaceuticals's earnings are expected to grow from $1.73 per share to $3.95 per share in the next year, which is a 128.32% increase. More Earnings Resources from MarketBeat Related Companies Repligen Earnings Madrigal Pharmaceuticals Earnings Halozyme Therapeutics Earnings Ionis Pharmaceuticals Earnings Alkermes Earnings Amicus Therapeutics Earnings Geron Earnings Celldex Therapeutics Earnings MannKind Earnings Dynavax Technologies Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report One coin could soar when Trump’s elected … (Ad)Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”Click here to find out more about what could be Trump and JD Vance’s favorite coin. This page (NASDAQ:LGND) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHas World War III already started?As global tensions are rising, so does the potential of direct conflict between the US and China. That's wh...Behind the Markets | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
